All In Biotech

Drug Trial Radar · NCT07850076

A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)

Official Title: A Phase 1/2 Multicenter, Open-label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460, a Lipid Nanoparticle Formulation of SyNTase Editing Components for In Vivo Editing of the Serine Protease Inhibitor A1 (SERPINA1) Gene in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
CRISPR TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).

Conditions

  • Alpha-1 Antitrypsin Deficiency (AATD)

Interventions

  • CTX460Drug

    CTX460 is a lipid nanoparticle (LNP) formulation of synthetic nucleotide template polymerase (SyNTase) editor for in vivo gene editing of the serine protease inhibitor A1 (SERPINA1) gene in adults with emphysema associated with severe alpha-1 antitrypsin deficiency (AATD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: To evaluate the safety and tolerability of CTX460 in adults with emphysema associated with severe AATD and to determine the recommended Phase 2 dose(s)Time frame: From CTX460 infusion up to 36 months
  2. Phase 2: To assess the efficacy of CTX460 in adults with severe AATD and emphysemaTime frame: 6 months from CTX460 infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Vincent's Hospital Melbourne

    Fitzroy, Melbourne, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.